<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Diabetic patients with moderate <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> (estimated glomerular filtration rate [eGFR] 30-59 mL/min/1.73 m(2)) are at particular cardiovascular risk </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="5001">Fenofibrate</z:chebi>'s safety in these patients is an issue because it may elevate plasma <z:chebi fb="0" ids="16737">creatinine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, guidelines regarding <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> dosing in <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> vary internationally </plain></SENT>
<SENT sid="3" pm="."><plain>We investigated <z:chebi fb="0" ids="5001">fenofibrate</z:chebi>'s effects on cardiovascular and <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) events, according to eGFR, in the <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> Intervention and Event Lowering in <z:mp ids='MP_0002055'>Diabetes</z:mp> (FIELD) Study </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: Type 2 diabetic patients (aged 50-75 years) with eGFR ≥30 mL/min/1.73 m(2) were randomly allocated to a fixed dose of <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> (200 mg daily) (n = 4,895) or placebo (n = 4,900) for 5 years </plain></SENT>
<SENT sid="5" pm="."><plain>Baseline renal function (Modification of Diet in <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">Renal Disease</z:e> equation) was grouped by eGFR (30-59, 60-89, and ≥90 mL/min/1.73 m(2)) </plain></SENT>
<SENT sid="6" pm="."><plain>The prespecified outcome was total cardiovascular events (composite of cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo>, and coronary/carotid revascularization) </plain></SENT>
<SENT sid="7" pm="."><plain>Serious adverse events and instances of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> (plasma <z:chebi fb="0" ids="16737">creatinine</z:chebi> &gt;400 μmol/L, dialysis, renal transplant, or renal <z:hpo ids='HP_0011420'>death</z:hpo>) were recorded </plain></SENT>
<SENT sid="8" pm="."><plain>Analysis was by intention to treat </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Overall, <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> reduced total cardiovascular events, compared with placebo (hazard ratio 0.89 [95% CI 0.80-0.99]; P = 0.035) </plain></SENT>
<SENT sid="10" pm="."><plain>This benefit was not statistically different across eGFR groupings (P = 0.2 for interaction) (eGFR 30-59 mL/min/1.73 m(2): 0.68 [0.47-0.97], P = 0.035; eGFR ≥90 mL/min/1.73 m(2): 0.85 [0.70-1.02], P = 0.08) </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> rates were similar between treatment arms, without adverse safety signals of <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> use in <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and moderate <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> benefit from long-term <z:chebi fb="0" ids="5001">fenofibrate</z:chebi>, without excess drug-related safety concerns compared with those with no or mild <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain><z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> treatment should not be contraindicated in moderate <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e>, suggesting that current guidelines may be too restrictive </plain></SENT>
</text></document>